Idvynso is a prescription oral therapy indicated as a complete regimen for the treatment of HIV-1 infection in adults who are already virologically suppressed on a stable antiretroviral regimen. Designed to replace an existing treatment in patients with no history of virologic failure and no known resistance to Doravirine, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). As a switch therapy, Idvynso offers a streamlined, once-daily oral regimen aimed at maintaining viral suppression while potentially improving treatment adherence and tolerability.

By leveraging the potency and resistance profile of doravirine, Idvynso supports long-term HIV management with a simplified approach for eligible patients. It is particularly relevant in treatment-experienced individuals seeking regimen optimization without compromising efficacy. As with all antiretroviral therapies, careful patient selection, resistance assessment, and ongoing clinical monitoring are essential to ensure sustained viral suppression and minimize the risk of treatment failure.